These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38257811)

  • 1. Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.
    Buchynskyi M; Oksenych V; Kamyshna I; Kamyshnyi O
    Viruses; 2024 Jan; 16(1):. PubMed ID: 38257811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public Health Impact of Paxlovid as Treatment for COVID-19, United States.
    Bai Y; Du Z; Wang L; Lau EHY; Fung IC; Holme P; Cowling BJ; Galvani AP; Krug RM; Meyers LA
    Emerg Infect Dis; 2024 Feb; 30(2):262-269. PubMed ID: 38181800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paxlovid for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 update: Prescription of Paxlovid by pharmacists.
    Med Lett Drugs Ther; 2022 Aug; 64(1656):e124. PubMed ID: 35921075
    [No Abstract]   [Full Text] [Related]  

  • 5. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
    Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
    Azanza JR; Mensa J; González Del Castillo J; Linares Rufo M; Molero JM; Madero Valle N; Barberán J
    Rev Esp Quimioter; 2022 Aug; 35(4):357-361. PubMed ID: 35822605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections.
    Hao X; Bao Z; Dai R; Wu X; Li X; Zhang M; Li H; Xu L; Qiao P; Liu X; Hu W; Zhang Z; Fang J; Zhou M; Wang W; Qu J
    Front Med; 2024 Feb; 18(1):169-179. PubMed ID: 37978164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    Tian F; Chen Z; Feng Q
    J Med Virol; 2023 Apr; 95(4):e28732. PubMed ID: 37183808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
    Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B
    Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study.
    Wang W; Wang YH; Huang CH; Hsieh TH; Ibarburu GH; Wei JC
    BMC Med; 2024 Mar; 22(1):117. PubMed ID: 38481216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
    Ombelet S; Castanares-Zapatero D; Desimpel F; Hulstaert F; Stordeur S; Roberfroid D
    J Med Virol; 2024 Feb; 96(2):e29434. PubMed ID: 38376947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covid-19: What is the evidence for the antiviral Paxlovid?
    Extance A
    BMJ; 2022 Apr; 377():o1037. PubMed ID: 35477536
    [No Abstract]   [Full Text] [Related]  

  • 14. Paxlovid Is Effective but Underused-Here's What the Latest Research Says About Rebound and More.
    Rubin R
    JAMA; 2024 Feb; 331(7):548-551. PubMed ID: 38294771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits.
    Rubin R
    JAMA; 2024 Oct; 332(13):1040-1042. PubMed ID: 39240544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paxlovid: Mechanism of Action, Synthesis, and
    Marzi M; Vakil MK; Bahmanyar M; Zarenezhad E
    Biomed Res Int; 2022; 2022():7341493. PubMed ID: 35845944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
    Henderson HI; Wohl DA; Fischer WA; Bartelt LA; van Duin D; Agil DM; Browne LE; Li KP; Moy A; Eron JJ; Napravnik S
    J Antimicrob Chemother; 2024 Apr; 79(4):859-867. PubMed ID: 38380946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High concentrations of nirmatrelvir/ritonavir in critically ill patients receiving continuous renal replacement therapy.
    Dong R; Huang Y; Ling X; Li L; Yu W; Jiang S
    Int J Antimicrob Agents; 2024 Jan; 63(1):106997. PubMed ID: 37848106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
    Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS
    Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.